Novo, however, vastly underestimated the appetite for its new weight-loss jab. Mr Doustdar says it planned for demand to be three times that of Saxenda, an older and less-effective weight-loss drug.

The true American killer What should have been the main lesson learned by the survivors of the pandemic of the old and the ill would appear to have been missed by those most vulnerable in these ...